Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144-53.

Kumada T, Toyoda H, Kiriyama S, et al. Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis C virus. J Gastroenterol. 2011;46(4):536-44.

Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol. 2016;54(12):1296-1305.

Dr. Philip J. Johnson

GALAD Model for Hepatocellular Carcinoma (HCC)

gender

afpl3

<p>Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD).</p>

GALAD Model for HCC

The GALAD Model for Hepatocellular Carcinoma (HCC) diagnoses HCC based on serum biomarkers.

AFP_L3

UKELD Score

CLIF-C ACLF

NAFLD Activity Score

EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.

Listen to the VACO co-creators break down how to use VACO\, what it does\, and what it doesn’t.

Calc Function